Jane Huang, CMO, Hematology at BeiGene, Ltd. (BGNE), sold 1,500 shares at $264.50 ($402K) on 2020-11-30, disclosed to the SEC on 2020-12-02.
Open-market sale of $402k BGNE by CMO, Hematology. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $256.00 | 104 | $27K | 6.6% |
| 2 | $260.06 | 100 | $26K | 6.5% |
| 3 | $262.06 | 200 | $52K | 13.0% |
| 4 | $263.28 | 100 | $26K | 6.6% |
| 5 | $264.50 | 200 | $53K | 13.2% |
| 6 | $266.75 | 300 |
| $80K |
| 19.9% |
| 7 | $269.05 | 100 | $27K | 6.7% |
| 8 | $275.45 | 100 | $28K | 6.9% |
| 9 | $277.22 | 100 | $28K | 6.9% |
| 10 | $278.92 | 100 | $28K | 6.9% |
| 11 | $285.05 | 96 | $27K | 6.8% |
| Total | $267.82 avg | 1,500 | $402K | 100% |
| Filing → |
| BGNE | SELL | 2021-12-02 | $755K | — | Filing → |
| BGNE | SELL | 2021-11-19 | $572K | — | Filing → |
| BGNE | SELL | 2021-10-21 | $559K | — | Filing → |